Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 16/4/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 16/4/21 | Free | Chief Financial Officer | 569,947 | 1.2238% | ||
| 16/4/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| +4.80% | +7.80% | +70.64% | +114.21% | 70.07B | |
| +17.12% | +11.50% | +49.15% | +87.30% | 52.87B | |
| +2.30% | -6.03% | -0.50% | +476.38% | 27.02B | |
| +2.26% | +0.65% | +49.19% | +10.30% | 23.61B | |
| -1.49% | -0.97% | -18.35% | -18.83% | 23.38B | |
| -6.00% | +13.71% | +244.39% | +443.26% | 19.43B | |
| +3.80% | +5.62% | +39.57% | -15.26% | 18.75B | |
| +0.38% | -3.15% | +20.39% | +589.77% | 15.85B | |
| +2.22% | -1.01% | +38.84% | +149.64% | 12.7B | |
| Average | +2.55% | -2.08% | +54.81% | +204.08% | 29.3B | |
| Weighted average by Cap. | +4.94% | -1.14% | +55.27% | +170.17% |
Employees
51
